Development And Toxicological Evolution Of Pegylated Chitosan Nanoparticle For The Simultaneous Delivery Of Silymarin And Dehydroemetine For The Enhance Hepatic Targeting

Abstract

The objective of the current study was to create biodegradable pegylated chitosan nanoparticles (SDNPs) and assess their potential for hepatic targeting on a single platform. The hepatoprotective effect of silymarin (SM) and dehydroemetine (DH) to the liver was investigated using the PEGylated chitosan nanoconjugate. Ionic gelation process was used to create the PEGylated Chitosan Nanoparticles, which were then tested for several optical and in-vitro characteristics. The MTT experiment on a human hepatocyte cell line revealed IC50 values for SDNPs and SM-DH of 0.45 and 0.67 M, respectively. The assessment of in vitro cell lines confirms improved uptake and biodistribution findings from confocal microscopy and apoptosis assay, which notably demonstrated increased accumulation of nanoconjugates in brain compared to free API. Compared to prohibited medications, the targeting of prospective SDNPs was found to be two times as significant. This leads to the conclusion that bidoegradable PEgylated chitosan nanoconjugates can be employed as possible nano-targeting to attach PEGylated chitosan nanoparticles for improved delivery of hepatoprotective medicines to the liver for better therapeutic outcome.